The company is committed to developing innovative products as the gene therapy pipeline expands, ensuring that self-insured employers have the necessary tools to manage these costs.

BCS Financial has launched a new stop loss product called Stop Loss GTS, specifically designed to protect self-funded employer groups from the high costs associated with gene therapies.

This innovative product allows employers to 'carve out' gene therapy costs into a separate stop loss policy, significantly reducing the risk of lasering and non-renewals on their traditional policies.

The costs of gene therapies can be staggering, ranging from $2 million to $4 million, making this coverage essential for self-insured employers.

BCS Financial has been developing solutions for gene therapy insurance since 2019, coinciding with the FDA's approval of the first gene therapies, and plans to continue innovating as new therapies emerge.

With over 70 years of experience in insurance and financial solutions, BCS Financial is licensed in all 50 states and holds an A (Excellent) rating from A.M. Best.

Stop Loss GTS is currently available for quoting in 45 states, making it a significant addition to BCS's offerings for managing the growing financial risks associated with gene therapies.

Mehb Khoja, Head of Large Claims Solutions at BCS, highlighted the challenges that self-funded employer groups face in managing these unprecedented costs under traditional insurance policies.